Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Michael Berk

Showing results (101-110 of 1,305) with videos related to

Pageof 131
Sort By:
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 12, 2020
Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomesMonojit Debnath, Moinak Banerjee, Michael Berk
Bipolar Disorders|August 31, 2024
Towards development of reliable criteria for at-risk states for bipolar disordersMichael Berk, Aswin Ratheesh, Jan Scott
The Australian and New Zealand Journal of Psychiatry|January 16, 2026
Managing the risk of pneumonia in elderly individuals with schizophrenia: The case for lowering the age limit for pneumococcal vaccinationElisa Pruss, Seetal Dodd, Michael Berk
The Journal of Clinical Psychiatry|April 29, 2003
A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodesLaura Barbosa, Michael Berk, Merryll Vorster
Journal of Evaluation in Clinical Practice|June 6, 2003
The evolution of clinical audit as a tool for quality improvementMichael Berk, Thomas Callaly, Mary Hyland
Journal of Psychiatry & Neuroscience : JPN|December 2, 2010
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionOlivia Dean, Frank Giorlando, Michael Berk
Neuroscience and Biobehavioral Reviews|December 16, 2014
Fetal programming of schizophrenia: select mechanismsMonojit Debnath, Ganesan Venkatasubramanian, Michael Berk
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 21, 2023
Infection-associated chronic disability: A transdiagnostic and translational opportunity for neuroscienceLivia J De Picker, Michael Berk
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 30, 2012
Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathwaysGeorge Anderson, Michael Maes, Michael Berk
Current Drug Safety|May 28, 2014
Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implicationsShilpa Aggarwal, Seetal Dodd, Michael Berk
Pageof 131

Showing results (101-110 of 1,305) with videos related to

Sort By:
Pageof 131
FASEB Journal : Official Publication of the Federation of American Societies for Experimental Biology|June 12, 2020
Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomesMonojit Debnath, Moinak Banerjee, Michael Berk
Bipolar Disorders|August 31, 2024
Towards development of reliable criteria for at-risk states for bipolar disordersMichael Berk, Aswin Ratheesh, Jan Scott
The Australian and New Zealand Journal of Psychiatry|January 16, 2026
Managing the risk of pneumonia in elderly individuals with schizophrenia: The case for lowering the age limit for pneumococcal vaccinationElisa Pruss, Seetal Dodd, Michael Berk
The Journal of Clinical Psychiatry|April 29, 2003
A double-blind, randomized, placebo-controlled trial of augmentation with lamotrigine or placebo in patients concomitantly treated with fluoxetine for resistant major depressive episodesLaura Barbosa, Michael Berk, Merryll Vorster
Journal of Evaluation in Clinical Practice|June 6, 2003
The evolution of clinical audit as a tool for quality improvementMichael Berk, Thomas Callaly, Mary Hyland
Journal of Psychiatry & Neuroscience : JPN|December 2, 2010
N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of actionOlivia Dean, Frank Giorlando, Michael Berk
Neuroscience and Biobehavioral Reviews|December 16, 2014
Fetal programming of schizophrenia: select mechanismsMonojit Debnath, Ganesan Venkatasubramanian, Michael Berk
European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology|October 21, 2023
Infection-associated chronic disability: A transdiagnostic and translational opportunity for neuroscienceLivia J De Picker, Michael Berk
Progress in Neuro-Psychopharmacology & Biological Psychiatry|August 30, 2012
Schizophrenia is primed for an increased expression of depression through activation of immuno-inflammatory, oxidative and nitrosative stress, and tryptophan catabolite pathwaysGeorge Anderson, Michael Maes, Michael Berk
Current Drug Safety|May 28, 2014
Restless leg syndrome associated with atypical antipsychotics: current status, pathophysiology, and clinical implicationsShilpa Aggarwal, Seetal Dodd, Michael Berk
Pageof 131